Doctors may soon be able to detect and monitor a patient’s cancer with a simple blood test, reducing or eliminating the need for more invasive procedures, according to Purdue University research.
W. Andy Tao, a professor of biochemistry and member of the Purdue University Center for Cancer Research and colleagues identified a series of proteins in blood plasma that, when elevated, signify that the patient has cancer. Their findings were published in the early edition of the Proceedings of the National Academy of Sciences.
Tao’s work was done with samples from breast cancer patients, but it is possible the method could work for any type of cancer and other types of diseases. The work relies on analysis of microvesicles and exosomes in blood plasma.
Protein phosphorylation, the addition of a phosphate group to a protein can lead to cancer cell formation. So phosphorylated proteins, known as phosphoproteins, have been seen as prime candidates for cancer biomarkers. Until now, however, scientists weren’t sure identification of phosphoproteins in blood was possible because the liver releases phosphatase into the bloodstream, which dephosphorylates proteins.
“There are so many types of cancer, even multiple forms for different types of cancer, that finding biomarkers has been discouraging,” Tao said. “This is definitely a breakthrough, showing the feasibility of using phosphoproteins in blood for detecting and monitoring diseases.”
Tao and his colleagues found nearly 2,400 phosphoproteins in a blood sample and identified 144 that were significantly elevated in cancer patients. The study compared 1-milliliter blood samples from 30 breast cancer patients with six healthy controls.
The researchers used centrifuges to separate plasma from red blood cells, and high-speed and ultra-high-speed centrifuges to further separate microvesicles and exosomes. Those particles, which are released from cells and enter the bloodstream, may play a role in intercellular communication and are thought to be involved in metastasis, spreading cancer from one place to another in the body. They also encapsulate phosphoproteins, which Tao’s team identified using mass spectrometry.
“Extracellular vesicles, which include exosomes and microvesicles, are membrane-encapsulated. They are stable, which is important,” Tao said. “The samples we used were 5 years old, and we were still able to identify phosphoproteins, suggesting this is a viable method for identifying disease biomarkers.”
A simple blood test for cancer would be far less invasive than scopes or biopsies that remove tissue. A doctor could also regularly test a cancer patient’s blood to understand the effectiveness of treatment and monitor patients after treatment to see if the cancer is returning.
“There is currently almost no way to monitor patients after treatment,” Tao said. “Doctors have to wait until cancer comes back.”
Timothy Ratliff, director of the Purdue University Center for Cancer Research, said the findings are promising for early detection of cancer.
“The vesicles and exosomes are present and released by all cancers, so it could be that there are general patterns for cancer tissues, but it’s more likely that Andy will develop patterns associated with different cancers. It’s really exciting,” Ratliff said. “Early detection in cancer is key and has been shown to clearly reduce the death rate associated with the disease.”
Tao plans to analyze increased levels of phosphoproteins in various types of cancer to determine whether there are patterns that would signify the type of cancer a patient has. His company, Tymora Analytical, is also developing technology that would allow doctors to insert blood samples onto a cartridge and analyze phosphoproteins present, eliminating the need for ultra-high-speed centrifuges that aren’t practical in clinical settings.
[osd_subscribe categories=’cancer-blood-test’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “CANCER BLOOD TEST”‘]
Receive an email update when we add a new CANCER BLOOD TEST article.
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- Chris Evert: Tennis great reveals ovarian cancer diagnosison January 14, 2022 at 11:10 pm
Tennis great Chris Evert has been diagnosed with ovarian cancer and is undergoing treatment. The 18-time grand slam singles champion revealed the diagnosis came in early December following a ...
- Boy, 8, Whose Face Had 'Swollen Up' Diagnosed With Rare Blood Canceron January 14, 2022 at 9:11 am
Jake Whittingham, from northern England, has acute lymphoblastic leukemia, a cancer of the white blood cells. "He continues to make us all amazingly proud," said the boy's uncle.
- Pancreatic Cancer Test Gets Validated for Newly Diagnosed Diabeteson January 13, 2022 at 3:28 pm
Researchers derived and validated a proprietary screening test to detect pancreatic cancer in people with new-onset diabetes. The test uses an epigenetic analysis of a 20 mL blood specimen.
- Blood test plus risk model may help improve selection for lung cancer screeningon January 13, 2022 at 5:35 am
A blood test based on a four-marker protein panel combined with an independent risk prediction model that accounts for smoking history significantly improved patient selection for lung cancer ...
- New type of blood test can be used to detect cancers as well as metastatic diseaseon January 12, 2022 at 4:38 pm
A University of Oxford study published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, outlines a new type of blood test that can be used to detect a ...
- Oxford cancer blood test detects tumors and metastasis earlyon January 11, 2022 at 4:50 pm
Cancer treatments have better outcomes if the disease is caught early, but unfortunately symptoms often don’t present until later. A new Oxford study demonstrates an experimental blood test that shows ...
- JPM 2022: Freenome passes $1B funding mark with $290M from Roche for cancer blood testson January 11, 2022 at 4:00 am
The latest of the blood testing company’s supersized fundraises came barely a month after its $300 million predecessor.
- Blood Test Better Predicts Who Can Benefit From Lung Cancer Screeningon January 10, 2022 at 8:41 am
A blood-based biomarker test combined with a lung cancer risk model was better at predicting who could benefit most from lung cancer screening.
- Blood test plus risk model can accurately determine who may benefit from lung cancer screeningon January 9, 2022 at 4:08 pm
A blood test, combined with a risk model based on an individual's history, more accurately determines who is likely to benefit from lung cancer screening than the current U.S. recommendation, ...
via Bing News